Venner Shipley welcomes Brookes IP Read more
  • Great Britain
  • Germany
  • France
  • China
  • Souht Korea

Anton Hutter


Partner, Patent Attorney

Partner, Patentanwalt

Associé, Patent Attorney

合伙人, 专利代理人

パートナー, 弁理士

파트너, 변리사

  • English (en)


Anton is a UK & European patent attorney, and works in our Guildford office. He is a partner in our chemical & life sciences team.

Anton specialises in biotechnology, pharmaceutical, chemical and medical device patent matters. In particular, he has a deep understanding of molecular biology, biochemistry, genetics, genomics & proteomics, therapeutic antibodies, immunology, immuno-oncology, plant biotechnology, peptides, biomarkers, bioinformatics, diagnostics, vaccines, stem cells, formulations, chemical engineering,  pharmaceuticals and SPC’s.  Anton is especially knowledgeable in patenting genome editing techniques, including CRISPR, as well as neurodegenerative disorders (primarily Alzheimer’s disease) and gene therapy inventions.

Anton has gained considerable experience in handling all aspects of patent practice, especially meeting inventors directly, and drafting and prosecuting patent applications before the UKIPO, the EPO and national patent offices. Anton has drafted hundreds of patent applications in the biotechnology, chemical and pharma sectors, and is experienced in managing international patent filing strategies for his clients.

Anton has significant experience of advising clients in relation to patent infringement and validity, freedom-to-operate clearances of third party patents, and providing due diligence opinions. Anton also enjoys complex opposition and appeal work, and regularly attends oral proceedings at the EPO.

Anton works for a broad spectrum of clients, and has extensive experience of working with academic institutions and associated technology transfer departments, university-derived spin-out companies, SME’s, as well as large multinational biotechnology and pharmaceutical companies. He is proactive, and provides his clients with clear, commercially relevant advice. Anton regularly lectures on a variety of IP-related topics, including patenting bioscience inventions.


Anton graduated from Nottingham University with an honours degree in Biochemistry & Genetics. He then attended UMIST where he obtained a master’s degree in Bioreactor Systems & Chemical Engineering, in which his research involved the design and construction of expression vectors for use in S. coelicolor. Anton also holds a PhD in Genetic Engineering, in which his research focused on the genetics of ethanol tolerance and production in the yeast, S. cerevisiae. He also has a certificate in Bioinformatics from Manchester University.

Professional Memberships

  • Fellow of the Chartered Institute of Patent Attorneys
  • Member of the European Patent Institute

Awards and Recognition

  • Legal 500 UK (PATMA: Patent Attorneys) – 2021 & 2020
  • IAM Strategy 300: The World’s Leading IP Strategists – 2021, 2020 & 2019

“Anton Hutter assembled a uniquely qualified team, and does an excellent job of coordinating their efforts for the good of my firm.” Client Testimonial, Legal 500 UK – 2022

“Anton Hutter stands out in that he makes time to deal with queries almost immediately, answering emails and phone calls with a speed that’s reassuring in times of concern or urgency. He has the knack of making one, or rather, one’s work, seem the most exciting and immediate project he has. He is in constant contact with us, convening meetings and raising red flags as soon as he foresees issues. We feel with this team that we’re in very safe and expert hands.” Client Testimonial, Legal 500 UK (PATMA: Patent Attorneys) – 2021

  • IAM Strategy 300: The World’s Leading IP Strategists 2021 recognises two Venner Shipley Professionals

  • Notice of UK public holiday 31 May 2021

  • An antidote to antibody patent confusion in Europe

  • Allie Elend and Anton Hutter ranked in IAM Strategy 300 Global Leaders guide

  • Allie Elend and Anton Hutter ranked in the 2020 edition of IAM Strategy 300

  • COVID-19 and IP

  • How to get your branding right

  • Patentability of methods of treatment and diagnosis

  • Venner Shipley gene therapy client, Quethera Limited, acquired by Astellas Pharmaceuticals

  • IP audits: taking stock of your intellectual property

  • CRISPR – the IP battle

  • Inside IP Spring Summer 2017